Rags to Rags for years ??
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EVSC #1 BREAKOUT BOARD!! Just popped up!
Hitting those .003 now. Its starting to be noticed
EVSC #1 BREAKOUT BOARD!! Just popped up!
Hitting those .003 now. Its starting to be noticed
EVSC .006 looks like we will see you soon
Starting to crack that fake wall by UBSS. On deck for EVSC .0038
Thats were the fun starts
CTSI Buy those UBSS shares, UBSS is not going to lower his ask
I contacted ihub this morning on why we were not on the breakout board yesterday. YES NOW EVSC WILL GET NOTICED!!
CTSI is trying to get his 375,000 shares at .0027 now
CTSI is trying to get his 375,000 shares at .0027 now
I dont think there is many shares out there to pick up. Look at L2 thin and alot of holders here. Something Big?!!
EVSC .0029 IS UP! Picking up steam
EVSC HUGE FIND >> This is from Nov 02,2012~ "Endovasc Inc" was a vendor along with the other Giants........
Global Drug-eluting Stents Market 2011-2015: The Global Drug-Eluting Stents Market to Reach US$6,278 Million By 2015 M2 Communications "M2 PressWIRE"
Dublin - Research and Markets (http://www.researchandmarkets.com/research/krv49d/global) has announced the addition of the "Global Drug-eluting Stents Market 2011-2015" report to their offering.
One of the key factors contributing to this market growth is the increasing incidence of cardiovascular diseases. The Global Drug-eluting Stents market has also been witnessing the use of bifurcated self-expanding coronary stents. However, the decline in the average selling price of drug-eluting stents could pose a challenge to the growth of this market.
Key vendors dominating this market space include Abbott Laboratories , Boston Scientific Corp. , Johnson and Johnson , Medtronic Inc. , MicroPort Scientific Corp. , and Terumo Medical Corp.
Other vendors mentioned in the report: Allvivo Vascular Inc. , Arterial Remodeling Technologies, Bayer MaterialScience , Biocompatibles Ltd. , Biosensors International Ltd. , Biotronik KG , Blue Medical, Cardiomind, Cook Medical Inc. , Devax Inc. , Endovasc Inc. , Goodman Co. Ltd. , InnoCore Technologies BV , Invatec, Lepu Medical Technology , MIV Therapeutics Inc. , PolyBioMed, Reva Medical Inc. , Stentys SA , SurModics Inc. , Translumina GmbH , X-Cell Medical Inc. and Xtent Inc.
Commenting on the report, an analyst from TechNavio's Healthcare team said: "Medical tourism is becoming popular globally because of the low-cost procedures in developing countries. Patients from the US and Europe visit countries such as the Philippines , India and China for percutaneous transluminal coronary angioplasty (PTCA) procedures and save around 60-70 percent of the treatment cost. Most of the implants from developed countries are now available in developing countries, and some indigenous manufacturers are offering Drug-eluting Stents (DES) at competitive prices. This attracts overseas patients to seek treatment in developing countries. This increasingly popular trend is expected to have a high impact on the market during the forecast period."
According to the report, one of the main drivers is the global increase in the aging population. Lower mortality rates, increased life expectancy, and population control in developing countries such as China , India and Japan have resulted in an increase in the aging population. The global aging population is expected to increase massively by 2050. The increase in the aging population results in an increase in PTCA surgeries. This in turn leads to increased use of DES, propelling the growth of the Global DES market.
Further, the report discusses that one of the major challenges in the Global DES market is the decline in the average selling price of DES.
For more information visit http://www.researchandmarkets.com/research/krv49d/global
CONTACT:
Research and Markets ,
Laura Wood ,
Senior Manager.
press@researchandmarkets.com
Fax from USA : 646-607-1907
Fax from rest of the world: +353-1-481-1716
Sector: Stents (http://www.researchandmarkets.com/categories.asp?cat_id=243&campaign_id=krv49d)
(( M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com)).
CTSI is fishing on the bid, raised it to .0026 then lowered it to .0024 Goodluck with that. Picking up STEAM!!
EVSC THIS IS A HUGE FIND >>>> This is from Nov 02,2012~ "Endovasc Inc" was a vendor along with the other Giants........
Global Drug-eluting Stents Market 2011-2015: The Global Drug-Eluting Stents Market to Reach US$6,278 Million By 2015 M2 Communications "M2 PressWIRE"
Dublin - Research and Markets (http://www.researchandmarkets.com/research/krv49d/global) has announced the addition of the "Global Drug-eluting Stents Market 2011-2015" report to their offering.
One of the key factors contributing to this market growth is the increasing incidence of cardiovascular diseases. The Global Drug-eluting Stents market has also been witnessing the use of bifurcated self-expanding coronary stents. However, the decline in the average selling price of drug-eluting stents could pose a challenge to the growth of this market.
Key vendors dominating this market space include Abbott Laboratories , Boston Scientific Corp. , Johnson and Johnson , Medtronic Inc. , MicroPort Scientific Corp. , and Terumo Medical Corp.
Other vendors mentioned in the report: Allvivo Vascular Inc. , Arterial Remodeling Technologies, Bayer MaterialScience , Biocompatibles Ltd. , Biosensors International Ltd. , Biotronik KG , Blue Medical, Cardiomind, Cook Medical Inc. , Devax Inc. , Endovasc Inc. , Goodman Co. Ltd. , InnoCore Technologies BV , Invatec, Lepu Medical Technology , MIV Therapeutics Inc. , PolyBioMed, Reva Medical Inc. , Stentys SA , SurModics Inc. , Translumina GmbH , X-Cell Medical Inc. and Xtent Inc.
Commenting on the report, an analyst from TechNavio's Healthcare team said: "Medical tourism is becoming popular globally because of the low-cost procedures in developing countries. Patients from the US and Europe visit countries such as the Philippines , India and China for percutaneous transluminal coronary angioplasty (PTCA) procedures and save around 60-70 percent of the treatment cost. Most of the implants from developed countries are now available in developing countries, and some indigenous manufacturers are offering Drug-eluting Stents (DES) at competitive prices. This attracts overseas patients to seek treatment in developing countries. This increasingly popular trend is expected to have a high impact on the market during the forecast period."
According to the report, one of the main drivers is the global increase in the aging population. Lower mortality rates, increased life expectancy, and population control in developing countries such as China , India and Japan have resulted in an increase in the aging population. The global aging population is expected to increase massively by 2050. The increase in the aging population results in an increase in PTCA surgeries. This in turn leads to increased use of DES, propelling the growth of the Global DES market.
Further, the report discusses that one of the major challenges in the Global DES market is the decline in the average selling price of DES.
For more information visit http://www.researchandmarkets.com/research/krv49d/global
CONTACT:
Research and Markets ,
Laura Wood ,
Senior Manager.
press@researchandmarkets.com
Fax from USA : 646-607-1907
Fax from rest of the world: +353-1-481-1716
Sector: Stents (http://www.researchandmarkets.com/categories.asp?cat_id=243&campaign_id=krv49d)
(( M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com)).
EVSC Up Up and Away. Its time guys to take a look. .0027 on deck!!
What is the significance of VFIN on the bid?
.0027 ON DECK
Wow look at that chart. EVCS is ROCKING!!
EVSC Can close out BIG!! Just like yesterday with 10 minutes to go in the session. I think some are hoping it drops to p/u cheap shares. It doesnt seem to be happenning. Something Big can be brewing here and some trying to maximize profit should stop playing games and get in now
Im holding tight, i say pennyland
EVSC HUGE FIND >> This is from Nov 02,2012~ "Endovasc Inc" was a vendor along with the other Giants........
Global Drug-eluting Stents Market 2011-2015: The Global Drug-Eluting Stents Market to Reach US$6,278 Million By 2015 M2 Communications "M2 PressWIRE"
Dublin - Research and Markets (http://www.researchandmarkets.com/research/krv49d/global) has announced the addition of the "Global Drug-eluting Stents Market 2011-2015" report to their offering.
One of the key factors contributing to this market growth is the increasing incidence of cardiovascular diseases. The Global Drug-eluting Stents market has also been witnessing the use of bifurcated self-expanding coronary stents. However, the decline in the average selling price of drug-eluting stents could pose a challenge to the growth of this market.
Key vendors dominating this market space include Abbott Laboratories , Boston Scientific Corp. , Johnson and Johnson , Medtronic Inc. , MicroPort Scientific Corp. , and Terumo Medical Corp.
Other vendors mentioned in the report: Allvivo Vascular Inc. , Arterial Remodeling Technologies, Bayer MaterialScience , Biocompatibles Ltd. , Biosensors International Ltd. , Biotronik KG , Blue Medical, Cardiomind, Cook Medical Inc. , Devax Inc. , Endovasc Inc. , Goodman Co. Ltd. , InnoCore Technologies BV , Invatec, Lepu Medical Technology , MIV Therapeutics Inc. , PolyBioMed, Reva Medical Inc. , Stentys SA , SurModics Inc. , Translumina GmbH , X-Cell Medical Inc. and Xtent Inc.
Commenting on the report, an analyst from TechNavio's Healthcare team said: "Medical tourism is becoming popular globally because of the low-cost procedures in developing countries. Patients from the US and Europe visit countries such as the Philippines , India and China for percutaneous transluminal coronary angioplasty (PTCA) procedures and save around 60-70 percent of the treatment cost. Most of the implants from developed countries are now available in developing countries, and some indigenous manufacturers are offering Drug-eluting Stents (DES) at competitive prices. This attracts overseas patients to seek treatment in developing countries. This increasingly popular trend is expected to have a high impact on the market during the forecast period."
According to the report, one of the main drivers is the global increase in the aging population. Lower mortality rates, increased life expectancy, and population control in developing countries such as China , India and Japan have resulted in an increase in the aging population. The global aging population is expected to increase massively by 2050. The increase in the aging population results in an increase in PTCA surgeries. This in turn leads to increased use of DES, propelling the growth of the Global DES market.
Further, the report discusses that one of the major challenges in the Global DES market is the decline in the average selling price of DES.
For more information visit http://www.researchandmarkets.com/research/krv49d/global
CONTACT:
Research and Markets ,
Laura Wood ,
Senior Manager.
press@researchandmarkets.com
Fax from USA : 646-607-1907
Fax from rest of the world: +353-1-481-1716
Sector: Stents (http://www.researchandmarkets.com/categories.asp?cat_id=243&campaign_id=krv49d)
(( M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com)).
Of course its holding, most shares were bought much higher than this, no one wants to sell, bidders trying to get cheap shares
L2 is getting thinner on the ask,
EVSC .0024 on deck Again
You just read my mind, EVSC $$
Looking stong here, expecting good things
LOL EVCS .0024 is up and .029 on deck
GO EVSC .0022 is up now and .0024 is on deck
EVSC .0022 on deck
It went from .0014 to .0006 yesterday then bounced right back up to .0015 on the 15 minute chart
Very little shares dumped
EVSC Bid is creeping up again :)
EVSC Boomage is an understatement
EVSC bids are creaping up, looks like a fine day brewing
Bid is rising :)
Clear skies from .003 to .01
VFIN Sitting large @.01
EVSC L2 is thin all the way to .01
ahh pennyland
EVSC Millions of shares were picked up .0025-.0027 at the end of the day.
EVSC up 216% yesterday
EVSC that was an awesome find, what a run in the making
EVSC is a hot stock, wait till it gets noticed
EVSC mentioned in the "Global Drug-eluting Stents Market 2011-2015" report, dated Oct. 2012, along with some other big names "Abbott Laboratories"
http://www.researchandmarkets.com/research/krv49d/global